Clinical trials: GERD
Barrett's Esophagus
Detection of Barrett s Esophagus in Patients Without GERD Symptoms
The purpose of this study is to develop a method to detect Barrett's esophagus (BE) in individuals with a new office-based diagnostic test.
- Trial name
- NCT04880044
- Testing
- EsoCheck/EsoGuard (EC/EG), Esophago-gastro-duodenoscopy (EGD)
- Where
- United States
- Volunteers
- 132 people
- Sponsor
- Case Comprehensive Cancer Center
Gastroesophageal Reflux Disease
Safety and Efficacy of Dexlansoprazole Modified Release Formulation to Treat Gastroesophageal Reflux Disease
The purpose of this study is to assess the efficacy and safety of Dexlansoprazole modified release (MR) (30 mg once daily [QD] or 60 mg QD) compared to placebo in relief of daytime and nighttime heartburn over 4 weeks in subjects…
- Trial name
- NCT00321984
- Testing
- Dexlansoprazole MR
- Where
- 153 sites in United States
- Volunteers
- 947 people
- Sponsor
- Takeda
Non-erosive Gastroesophageal Reflux Disease
Phase 3 Study of TAK-438 10 mg in the Treatment of Non-Erosive Gastroesophageal Reflux Disease (NERD)
The purpose of this study was to evaluate the efficacy and safety of oral TAK-438 10 mg once-daily in the treatment of non-erosive gastroesophageal reflux disease (NERD).
- Trial name
- NCT02954848
- Testing
- TAK-438 10 mg
- Where
- 30 sites in Japan
- Volunteers
- 484 people
- Sponsor
- Takeda
Gastroesophageal Reflux Disease, Morbid Obesity
Gastroesophageal Reflux Disease (GERD) Before and After Gastric Bypass
The hypothesis of this study was that gastric bypass (GBP) ameliorates gastroesophageal reflux disease (GERD) in morbidly obese patients.
- Trial name
- NCT00951093
- Testing
- Gastric bypass
- Where
- Brazil
- Volunteers
- 53 people
- Sponsor
- Clinica Gastrobese
Gastroesophageal Reflux
Efficacy of Dexlansoprazole MR on Heartburn Control in Participants Previously Receiving Twice Daily Proton Pump Inhibitor Therapy
The purpose of this study is to determine if patients with well-controlled heartburn symptoms on twice-daily proton pump inhibitor therapy remain well-controlled after stepping down to once-daily (QD) dexlansoprazole modified…
- Trial name
- NCT00847808
- Testing
- Dexlansoprazole MR QD
- Where
- 52 sites in United States
- Volunteers
- 178 people
- Sponsor
- Takeda
Refractory Reflux Esophagitis
Double-blind Comparative Study of E3810 Tablets (10 or 20 mg b.i.d.) to Evaluate Efficacy and Safety in Patients With Refractory Reflux Esophagitis
The purpose of this study is to evaluate the efficacy and safety of E3810 tablets in patients with Proton Pump Inhibitor-resistant reflux esophagitis.
- Trial name
- NCT00770913
- Testing
- E3810
- Where
- 54 sites in Japan
- Volunteers
- 337 people
- Sponsor
- Eisai Co., Ltd.
Gastroesophageal Reflux Disease
An Explorative Trial to Evaluate the Pharmacodynamic Effect of SPD557 on Reflux Parameters in Refractory GERD Patients
The purpose of this trial is to investigate the pharmacodynamic effect on reflux parameters of SPD557 tablets (0.5 mg t.i.d., on top of PPI treatment) in patients with Gastroesophageal Reflux Disease (GERD) with persistent…
- Trial name
- NCT01370863
- Testing
- SPD557
- Where
- 15 sites in Belgium, France and 4 more
- Volunteers
- 67 people
- Sponsor
- Shire
Gastroesophageal Reflux
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Vonoprazan in Adolescents With Symptomatic Gastroesophageal Reflux Disease
The primary objective of this study is to evaluate the pharmacokinetic profile of vonoprazan in adolescent participants with symptomatic gastroesophageal reflux disease (GERD).
- Trial name
- NCT05343364
- Testing
- Vonoprazan
- Where
- 10 sites in United States
- Volunteers
- 24 people
- Sponsor
- Phathom Pharmaceuticals, Inc.
Gastroesophageal Reflux Disease
Treatment of Gastroesophageal Reflux Disease in 12-16 Year Old Patients With Rabeprazole
The primary objective of this study is to collect safety information on rabeprazole 10 mg and 20 mg in the treatment of gastroesophageal reflux disease (GERD) in children aged 12 to 16 years.
- Trial name
- NCT00132496
- Testing
- rabeprazole sodium
- Where
- 25 sites in United States
- Volunteers
- 111 people
- Sponsor
- Eisai Inc.
Gastroesophageal Reflux Disease
A Study to Evaluate Vonoprazan in Children Who Have Symptomatic Gastroesophageal Reflux Disease
The aim of this study is to evaluate the pharmacokinetic (PK) profile of vonoprazan (10 or 20 mg once daily [QD]) in children ≥ 6 to < 12 years of age who have symptomatic Gastroesophageal Reflux Disease (GERD).
- Trial name
- NCT06106022
- Testing
- Vonoprazan
- Where
- 13 sites in United States
- Volunteers
- 22 people
- Sponsor
- Phathom Pharmaceuticals, Inc.
Eosinophilic Esophagitis
Fluticasone Versus Esomeprazole to Treat Eosinophilic Esophagitis
The purpose of this study is to assess the clinical efficacy of proton pump inhibitors in comparison to aerosolized swallowed steroids for the treatment of eosinophilic esophagitis (EE).
- Trial name
- NCT00895817
- Testing
- Swallowed fluticasone, Esomeprazole
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Walter Reed Army Medical Center
Erosive Esophagitis, Heartburn
A Study to Evaluate Vonoprazan Concentrations in Breast Milk of Healthy Lactating Women Receiving Vonoprazan 20 mg Once Daily or Vonoprazan 20 mg Twice Daily
The primary objective is to determine the pharmacokinetics (PK) of vonoprazan in breast milk of healthy lactating women who have received vonoprazan administered once daily or vonoprazan 20 mg administered twice daily for 4…
- Conditions
- Erosive Esophagitis, Heartburn, Symptomatic Nonerosive Gasroesophageal Reflux Disease, Helicobacter Pylori Infection
- Trial name
- NCT06391177
- Testing
- Vonoprazan
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Phathom Pharmaceuticals, Inc.
Sleep Disorders, Non-Erosive Reflux Disease
Pantoprazole 20/40 mg in the Treatment of Symptomatic Reflux Disease With Focus on Sleep Disorders
The aim of the study was to evaluate the effect of pantoprazole on sleep disorders in patients with NERD (non-erosive reflux disease) or eGERD (erosive gastroesophageal reflux disease).
- Conditions
- Sleep Disorders, Non-Erosive Reflux Disease, Gastroesophageal Reflux Disease
- Trial name
- PANDA (NCT00830115)
- Testing
- Pantoprazole
- Where
- 201 sites in Germany
- Volunteers
- 1,045 people
- Sponsor
- Nycomed
GERD, Gastroesophageal Reflux
Observational Study of Anti-Reflux Surgery
The Anti-Reflux Surgical Study has been established to: Collect data about anti-reflux surgical treatment options (magnetic sphincter augmentation and Fundoplication) in everyday clinical practice Track the clinical course of…
- Conditions
- GERD, Gastroesophageal Reflux, Gastro Esophageal Reflux
- Trial name
- NCT01624506
- Where
- 21 sites in Austria, Germany and 2 more
- Volunteers
- 760 people
- Sponsor
- Torax Medical Incorporated
Gastroesophageal Reflux
Fexofenadine Use in Gastroesophageal Reflux Symptoms
The investigators wish to study the effectiveness of Fexofenadine (an over the counter allergy pill) for the treatment of gastroesophageal reflux symptoms in patients who still have symptoms despite being on a proton pump…
- Trial name
- NCT03425097
- Testing
- Fexofenadine
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Stanford University
Barrett Esophagus, Gastroesophageal Reflux
Assessment of Zegerid on Esophageal pH in Patients With Barrett's Esophagus
The purpose of this research study is to assess how safe, effective (how well it works), and tolerable (to put up with) the drug Zegerid is in reducing reflux episodes in patients who have both gastroesophageal reflux disease…
- Trial name
- NCT01129778
- Testing
- Zegerid (proton pump inhibitor), Bravo pH monitoring
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Stanford University
Gastro-oesophageal Reflux
A Study to Compare the Number of Patients With Gastro-Oesophageal Reflux Disease (GORD) Achieving Heartburn and Regurgitation Symptom Resolution After Treatment With Either Rabeprazole Sodium 20mg, Esomeprazole 20mg or Esomeprazole 40mg
The primary objective of this study is to compare, the number of patients with heartburn and regurgitation symptom resolution after treatment with either rabeprazole 20 mg, esomeprazole 20 mg or esomeprazole 40 mg.
- Trial name
- NCT00464308
- Testing
- Esomeprazole, Rabeprazole
- Where
- 25 sites in Australia
- Volunteers
- 1,392 people
- Sponsor
- Janssen-Cilag Pty Ltd
Otitis Media With Effusion
A Clinical Trial of Proton Pump Inhibitors to Treat Children With Chronic Otitis Media With Effusion
This study is being done to see if reflux of stomach fluid might be a cause of chronic fluid in the ears. Our hypothesis is that treatment with an anti-reflux medication (lansoprazole) will increase the rate of resolution of…
- Trial name
- NCT00546117
- Testing
- lansoprazole
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Washington University School of Medicine
Gastroesophageal Reflux
Comparison of Vonoprazan to Esomeprazole in Participants With Symptomatic GERD Who Responded Partially to a High Dose of Proton Pump Inhibitor (PPI)
The purpose of this study is to determine the effect of vonoprazan compared to esomeprazole for preventing heartburn symptoms over a 4-week treatment period in participants who have a partial response to treatment with…
- Trial name
- NCT02743949
- Testing
- Vonoprazan, Esomeprazole
- Where
- 39 sites in Belgium, Bulgaria and 4 more
- Volunteers
- 256 people
- Sponsor
- Takeda
Barrett Esophagus, Esophageal Adenocarcinoma
Rapid Assessment of Esophageal Adenocarcinoma Risk Test
This study aims to evaluate the acceptability of a new non-invasive screening device to test for Barrett's esophagus. The investigators will prospectively enroll 100 patients to undergo Cytosponge testing.
- Trial name
- REACT (NCT03366012)
- Testing
- Cytosponge
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Columbia University